Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Bortezomib (Primary) ; Irinotecan
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
    • 30 Jun 2009 Additional lead trial investigator identified as reported by New Jersey Cancer Trial Connect.
    • 02 Jun 2009 Interim results from 62 (of 71 enrolled) patients were presented at ASCO 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top